Oryzon Genomics SA
LSE:0RDB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Oryzon Genomics SA
LSE:0RDB
|
ES |
|
V
|
Voxel SA
WSE:VOX
|
PL |
|
P
|
Pampa Energia SA
BCBA:PAMP
|
AR |
|
GMO Pepabo Inc
TSE:3633
|
JP |
|
P
|
Post Holdings Inc
F:2PO
|
US |
Intrinsic Value
Is 0RDB undervalued or overvalued?
See the intrinsic value estimate for 
Oryzon Genomics SA and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
0RDB looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with 0RDB’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Oryzon Genomics Does
Oryzon Genomics is a drug development company focused on medicines that change how genes are switched on and off. Its main work is discovering and testing epigenetic drugs, especially compounds that block LSD1, an enzyme involved in cancer and some brain disorders. The company does not sell everyday consumer products; it builds drug candidates that may eventually be licensed or sold as prescription medicines if they win approval.
- Headquarters
- Spain ES
- Employees
- 46
- IPO date
- Dec 10, 2015
Earnings Waterfall
Oryzon Genomics SA
The intrinsic value for Oryzon Genomics SA (0RDB) under the Base Case is hidden EUR.
Compared with the current market price of 2.5 EUR, the stock appears hidden.